1887

Access Microbiology open research platform logo

Volume 2, Issue 3

The first case of HIV-2 in Scotland Open Access

Abstract

HIV-1 infects an estimated 37 million people worldwide, while the rarer HIV-2 infects 1–2 million worldwide. HIV-2 is mainly restricted to West African countries. The majority of patients in Scotland are diagnosed with HIV-1, but in 2013 the West of Scotland Specialist Virology Centre (WoSSVC) diagnosed Scotland’s first HIV-2 positive case in a patient from Côte d’Ivoire. HIV-2 differs from HIV-1 in terms of structural viral proteins, viral transmissibility, prolonged period of latency, intrinsic resistance to certain antivirals and how to monitor the effectiveness of treatment. Over the course of 5 years the patient has required several changes in treatment due to both side effects and pill burden. This case highlights the complexity of HIV-2 patient management over time.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antiretrovirals , diagnosis , HIV2 and treatment
© 2020 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000087
2019-12-10
2023-01-31
Loading full text...

Full text loading...

/deliver/fulltext/acmi/2/3/acmi000087.html?itemId=/content/journal/acmi/10.1099/acmi.0.000087&mimeType=html&fmt=ahah

References

  1. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011; 1:a006841 [View Article][PubMed]
     [Google Scholar]
  2. Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C et al. HIV-2 molecular epidemiology. Infect Genet Evol 2016; 46:233–240 [View Article][PubMed]
     [Google Scholar]
  3. Fonquernie L, Eholié SP, Damond F, Lacombe K, Girard P-M et al. Failure of HIV-2 viral load assay in a severely immunodeficient patient: clinical and therapeutic management issues. Trans R Soc Trop Med Hyg 2006; 100:282–284 [View Article][PubMed]
     [Google Scholar]
  4. Smith SM, Christian D, de Lame V, Shah U, Austin L et al. Isolation of a new HIV-2 group in the US. Retrovirology 2008; 5:103 [View Article][PubMed]
     [Google Scholar]
  5. Ibe S, Yokomaku Y, Shiino T, Tanaka R, Hattori J et al. Hiv-2 CRF01_AB: first circulating recombinant form of HIV-2. J Acquir Immune Defic Syndr 2010; 54:241–247 [View Article][PubMed]
     [Google Scholar]
  6. Gottlieb GS, Hawes SE, Agne HD, Stern JE, Critchlow CW et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895–890 [View Article][PubMed]
     [Google Scholar]
  7. Hawes SE, Sow PS, Stern JE, Critchlow CW, Gottlieb GS et al. Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 2008; 22:2517–2525 [View Article][PubMed]
     [Google Scholar]
  8. Donnelly C, Leisenring W, Kanki P, Awerbuch T, Sandberg S et al. Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal. Bull Math Biol 1993; 55:731–743 [View Article][PubMed]
     [Google Scholar]
  9. Piedade J, Venenno T, Prieto E, Albuquerque R, Esteves A et al. Longstanding presence of HIV-2 infection in Guinea-Bissau (West Africa). Acta Trop 2000; 76:119–124 [View Article][PubMed]
     [Google Scholar]
  10. Fryer HR, Van Tienen C, Van Der Loeff MS, Aaby P, Da Silva ZJ et al. Predicting the extinction of HIV-2 in rural Guinea-Bissau. AIDS 2015; 29:2479–2486 [View Article][PubMed]
     [Google Scholar]
  11. Evans LA, Moreau J, Odehouri K, Seto D, Thomson-Honnebier G et al. Simultaneous isolation of HIV-1 and HIV-2 from an AIDS patient. Lancet 1988; 2:1389–1391 [View Article][PubMed]
     [Google Scholar]
  12. Smallman-Raynor M, Cliff A. The spread of human immunodeficiency virus type 2 into Europe: a geographical analysis. Int J Epidemiol 1991; 20:480–489 [View Article][PubMed]
     [Google Scholar]
  13. Faria NR, Hodges-Mameletzis I, Silva JC, Rodés B, Erasmus S et al. Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. J Gen Virol 2012; 93:889–899 [View Article][PubMed]
     [Google Scholar]
  14. Rübsamen-Waigmann H, Briesen HV, Maniar JK, Rao PK, Scholz C et al. Spread of HIV-2 in India. Lancet 1991; 337:550–551 [View Article][PubMed]
     [Google Scholar]
  15. Kannangai R, Ramalingam S, Castillo RC, Babu PG, John TJ et al. Hiv-2 status in southern India. Trans R Soc Trop Med Hyg 1999; 93:30–31 [View Article][PubMed]
     [Google Scholar]
  16. Valadas E, França L, Sousa S, Antunes F. 20 years of HIV-2 infection in Portugal: trends and changes in epidemiology. Clin Infect Dis 2009; 48:1166–1167 [View Article][PubMed]
     [Google Scholar]
  17. de Mendoza C, Cabezas T, Caballero E, Requena S, Amengual MJ et al. Hiv type 2 epidemic in Spain: challenges and missing opportunities. AIDS 2017; 31:1353–1362 [View Article][PubMed]
     [Google Scholar]
  18. Elamin W, Biddy DF, Clark DA, Anderson J, Deayton JR. HIV-2 in the United Kingdom - the North-East London cohort. HIV Med 2013; 14:131
     [Google Scholar]
  19. Gilleece Y, Chadwick DR, Breuer J, Hawkins D, Smit E et al. British HIV association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med 2010; 11:611–619 [View Article][PubMed]
     [Google Scholar]
  20. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI et al. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A 2002; 99:14410–14415 [View Article][PubMed]
     [Google Scholar]
  21. Damond F, Benard A, Balotta C, Böni J, Cotten M et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. J Clin Microbiol 2011; 49:3491–3497 [View Article][PubMed]
     [Google Scholar]
  22. Malloch L, Kadivar K, Putz J, Levett PN, Tang J et al. Comparative evaluation of the Bio-Rad Geenius HIV-1/2 confirmatory assay and the Bio-Rad Multispot HIV-1/2 rapid test as an alternative differentiation assay for CLSI M53 algorithm-I. J Clin Virol 2013; 58S:e85–e91 [View Article][PubMed]
     [Google Scholar]
  23. Montesinos I, Eykmans J, Delforge M-L. Evaluation of the Bio-Rad Geenius HIV-1/2 test as a confirmatory assay. J Clin Virol 2014; 60:399–401 [View Article][PubMed]
     [Google Scholar]
  24. Hønge BL, Jespersen S, Medina C, Té DS, da Silva ZJ et al. The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections. HIV Med 2018; 19:403–410 [View Article][PubMed]
     [Google Scholar]
  25. van der Loeff MFS, Larke N, Kaye S, Berry N, Ariyoshi K et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology 2010; 7:46 [View Article][PubMed]
     [Google Scholar]
  26. Delarue S, Didier E, Damond F, Ponscarme D, Brengle-Pesce K et al. Highly sensitive plasma RNA quantification by real-time PCR in HIV-2 group A and group B infection. J Clin Virol 2013; 58:461–467 [View Article][PubMed]
     [Google Scholar]
  27. Tchounga B, Ekouevi DK, Balestre E, Dabis F. Mortality and survival patterns of people living with HIV-2. Curr Opin HIV AIDS 2016; 11:537–544 [View Article][PubMed]
     [Google Scholar]
  28. Hansmann A, Schim van der Loeff MF, Kaye S, Awasana AA, Sarge-Njie R et al. Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2-infected women in a community-based cohort in the Gambia. J Acquir Immune Defic Syndr 2005; 38:335–341[PubMed]
     [Google Scholar]
  29. Onyango CO, Leligdowicz A, Yokoyama M, Sato H, Song H et al. Hiv-2 capsids distinguish high and low virus load patients in a West African community cohort. Vaccine 2010; 28:B60–B67 [View Article][PubMed]
     [Google Scholar]
  30. Styer LM, Miller TT, Parker MM. Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control. J Clin Virol 2013; 58:e127–e133 [View Article][PubMed]
     [Google Scholar]
  31. Matheron S, Damond F, Benard A, Taieb A, Campa P et al. Cd4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 2006; 20:459–462 [View Article][PubMed]
     [Google Scholar]
  32. Camacho RJ. Special aspects of the treatment of HIV-2-infected patients. Intervirology 2012; 55:179–183 [View Article][PubMed]
     [Google Scholar]
  33. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. Hiv-1 drug resistance and resistance testing. Infect Genet Evol 2016; 46:292–307 [View Article][PubMed]
     [Google Scholar]
  34. Ekouevi DK, Tchounga BK, Coffie PA, Tegbe J, Anderson AM et al. Antiretroviral therapy response among HIV-2 infected patients: a systematic review. BMC Infect Dis 2014; 14:461 [View Article][PubMed]
     [Google Scholar]
  35. Menéndez-Arias L, Alvarez M. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antiviral Res 2014; 102:70–86 [View Article][PubMed]
     [Google Scholar]
  36. Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS et al. Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 2009; 199:1323–1326 [View Article][PubMed]
     [Google Scholar]
  37. Charpentier C, Camacho R, Ruelle J, Eberle J, Gürtler L et al. HIV-2EU-Supporting standardized HIV-2 drug-resistance interpretation in Europe: an update. Clin Infect Dis 2015; 61:1346–1347 [View Article][PubMed]
     [Google Scholar]
  38. Benard A, van Sighem A, Taieb A, Valadas E, Ruelle J et al. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHIEV2E collaboration Study Group. Clin Infect Dis 2011; 52:1257–1266 [View Article][PubMed]
     [Google Scholar]
  39. Boffito M, Jackson A, Pozniak A, Giraudon M, Kulkarni R et al. Effect of a modified saquinavir/ritonavir dosing regimen with lower dose lead-in phase on QTc interval, pharmacokinetics, antiviral activity and safety in treatment-naïve HIV-1-infected patients. Drugs R D 2015; 15:141–153 [View Article][PubMed]
     [Google Scholar]
  40. Ray AS, Fordyce MW, Hitchcock MJM. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res 2016; 125:63–70 [View Article]
     [Google Scholar]
  41. Bercoff DP, Triqueneaux P, Lambert C, Oumar AA, Ternes A-M et al. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology 2010; 7:98 [View Article][PubMed]
     [Google Scholar]
  42. Gottlieb GS, Smith RA, Dia Badiane NM, Ba S, Hawes SE et al. Hiv-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. PLoS One 2011; 6:e22204 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/acmi/10.1099/acmi.0.000087
Loading
The first case of HIV-2 in Scotland
Access Microbiology 2, e000087 (2020); https://doi.org/10.1099/acmi.0.000087
/content/journal/acmi/10.1099/acmi.0.000087
/content/journal/acmi/10.1099/acmi.0.000087
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error